@Article{,
AUTHOR = {Fred Saad},
TITLE = {Bone loss in prostate cancer: evaluation, treatment and prevention},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {12},
YEAR = {2005},
NUMBER = {Suppl.1},
PAGES = {71--76},
URL = {http://www.techscience.com/CJU/v12nSuppl.1/63387},
ISSN = {1488-5581},
ABSTRACT = {Modern medicine offers multiple treatment options to
prolong the survival of patients with prostate cancer.
However, in the absence of adequate supportive care, the
systemic effects of prostate cancer and therapies such as
androgen deprivation therapy (ADT) can undermine
skeletal integrity, resulting in skeletal complications.
Skeletal morbidity contributes to the erosion in quality of
life in patients with prostate cancer. These patients are at
risk for fractures from cancer treatment-induced bone loss
and, later on, pathologic fractures from bone metastases,
which may occur during the progression of prostate cancer.
Several supportive care options are available to prevent
generalized and focal bone loss, including calcium and
vitamin D supplements and bisphosphonates. Oral
calcium and vitamin D supplementation alone, however,
appears to be insufficient to prevent bone loss during ADT.
Bisphosphonates may be beneficial in preventing bone loss
and eventually reducing skeletal morbidity due to prostate
cancer and ADT.},
DOI = {}
}